Nutriband Inc. Warrant NTRBW

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
44/100
Developing

Ranked against 712 peers in Biotechnology

About Nutriband Inc. Warrant

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and … Full NTRBW analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.87), suggesting sticky customer base.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.80), demonstrating pricing resilience across cycles.

Key risks

  • ROIC Below WACC or Peers ROIC at 25.9th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.22), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
43
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where NTRBW ranks in Biotechnology

Nutriband Inc. Warrant ranks #310 of 713 scored companies in Biotechnology by moat score — the top 43%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
306 Orchestra BioMed Holdings, Inc. OBIO 45/100 Developing
307 IN8bio, Inc. INAB 45/100 Developing
308 Kezar Life Sciences, Inc. KZR 45/100 Developing
309 Bicara Therapeutics Inc. BCAX 44/100 Developing
310 Nutriband Inc. Warrant NTRBW 44/100 Developing
311 Cartesian Therapeutics, Inc. RNAC 44/100 Developing
312 ACELYRIN, INC. SLRN 44/100 Developing
313 Nutriband Inc. NTRB 44/100 Developing
314 Clearside Biomedical, Inc. CLSD 44/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How NTRBW scores on the Corporate Default defenses

Pricing Power

Score 43 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 48 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 70 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 26 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 42 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 40 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding NTRBW's moat

What is Nutriband Inc. Warrant's moat score?

Nutriband Inc. Warrant (NTRBW) scores 44 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #310 of 713 scored companies in Biotechnology, the top 43%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (70/100) and its weakest is Capital Efficiency (26/100).

How does Nutriband Inc. Warrant compare with other Biotechnology companies?

Nutriband Inc. Warrant ranks #310 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Bicara Therapeutics Inc. (BCAX) at 44 just above it and Cartesian Therapeutics, Inc. (RNAC) at 44 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Nutriband Inc. Warrant scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Nutriband Inc. Warrant?

The Corporate Default template measures 6 defenses, and NTRBW scores: Pricing Power (43), Cost Advantage (48), Customer Stickiness (70), Capital Efficiency (26), Resilience (42), Scale & Market Position (40). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000